Schedule 13D ownership disclosure

Aclaris Therapeutics, Inc.

Security class unavailable

Event date: 2017-11-15

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
5.5000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001615774-17-006790
Form type
SC 13D/A
Filer
Aclaris Therapeutics, Inc.
CIK
CIK 1557746
Filed
Nov 16, 2017
Reporting period
Nov 15, 2017
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub